Myomo (0M61) Stock Price & Analysis
0M61 Stock Chart & Stats
- Day’s Range
- EUR 1.09 - EUR 1.14
- 52-Week Range
- EUR 0.54 - EUR 1.60
- Previous Close
- EUR 1.13
- Volume
- 0
- Average Volume (3M)
- 171
- Market Cap
- EUR 43.98M
- Enterprise Value
- EUR 51.03M
- Total Cash (Recent Filing)
- EUR 13.45M
- Total Debt (Recent Filing)
- EUR 20.08M
- Price to Earnings (P/E)
- ―
- Beta
- 1.25
- Next Earnings
- Nov 11, 2026 (Est.)
- EPS Estimate
- -0.07
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Specialized Wearable Medical-device Niche
Myomo addresses a specialized clinical need with a wearable device designed to restore functional movement. This focused product positioning can support durable differentiation, clinician referral activity, and patient demand as awareness of assistive technology expands.
Strong Gross-margin Profile
A gross margin near 68% provides meaningful contribution from each device delivered and creates potential operating leverage as revenue scales. Although profitability is not yet established, the margin profile gives Myomo a foundation to improve earnings if commercial growth outpaces fixed costs.
Revenue Has Scaled With Continued Growth
Revenue expansion to approximately $43.3 million indicates that Myomo has built a meaningful commercial base for its product. Continued growth can broaden operating scale, strengthen market reach, and improve the prospects of converting gross profit into sustainable earnings over time.
Bears Say
Persistent Operating And Net Losses
Large operating and net losses show that Myomo has not yet demonstrated durable operating leverage despite revenue growth and strong gross margins. Continued losses can restrict internally funded investment, prolong reliance on external capital, and delay the path to sustainable profitability.
Worsening Cash Burn
Negative operating and free cash flow indicate that the business is consuming cash rather than funding its own expansion. The roughly 49% deterioration in free cash flow increases dependence on financing and leaves less flexibility to absorb execution challenges while pursuing growth.
Higher Leverage And Shrinking Equity
Rising debt alongside a shrinking equity base reduces balance-sheet flexibility and increases financing risk while losses continue. Higher leverage can constrain capital allocation, raise the importance of future funding access, and make the company more vulnerable if cash generation does not improve.
Myomo News
0M61 FAQ
What was Myomo’s price range in the past 12 months?
What is Myomo’s market cap?
When is Myomo’s upcoming earnings report date?
How were Myomo’s earnings last quarter?
Is Myomo overvalued?
Does Myomo pay dividends?
What is Myomo’s EPS estimate?
How many shares outstanding does Myomo have?
What happened to Myomo’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Myomo?
What is the TipRanks Smart Score and how is it calculated?
Myomo Stock Smart Score
Company Description
Myomo
Myomo, Inc. is a medical technology company specializing in wearable robotics. The company engineers and manufactures advanced myoelectric orthoses, primarily for individuals in the United States who experience neuromuscular impairments. Its flagship product, MyoPro, is an upper-limb brace that utilizes muscle signals to assist patients with weak or paralyzed arms, thereby enhancing their ability to perform daily activities. These devices aim to restore function for both adult and adolescent patients suffering from various neurological conditions, including stroke, spinal cord injury, traumatic brain injury, and brachial plexus injuries. Myomo distributes its innovative solutions through a network that includes orthotics and prosthetics providers, rehabilitation hospitals, the Veterans Health Administration, and additional distributors. Established in 2004, Myomo, Inc. maintains its corporate headquarters in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Paul R. Gudonis
- Employees
- 195
- Website
- www.myomo.com
- Address
- 45 Blue Sky Dr., Burlington, MA, 01803, US
Myomo (0M61) Earnings & Revenues
0M61 Earnings Call
Earnings Call SentimentPositive
The call highlights steady, incremental progress: modest top-line growth (Q1 revenue +3%), improved gross margin (+100 bps), lower operating expenses (-1%), improved adjusted EBITDA (negative $2.3M vs negative $2.8M), strong shifts toward recurring revenue (49% of revenue vs 25% prior year), and robust international and O&P channel growth (international +53% YoY; U.S. O&P +79% YoY). Management provided constructive operational updates including payer contracting (covered lives up to 158M), product advances (mobile app reducing material costs ~10%, MyoPro 3 development), and a growing referral network (150+ rehab facilities, Autoboc partnership). Lowlights include continued net losses, dependency on a multi-quarter revenue cycle, macro pressures in Medicare Advantage and a decline in Medicare Part B dollar contribution, and some short-term margin pressure from higher on-site fitting costs. Overall, positive operational momentum and improving financial metrics outweigh remaining profitability and execution risks.
View all DE:0M61 earnings summaries0M61 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 6 | 11 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 3 | 0 | 9 |
